A systematic review assessing the effectiveness of interventions to improve persistence with anti-resorptive therapy in women at high risk of clinical fracture

Family Practice

Volumn 27, Issue 6, 2010, Pages 593-603

  White, H J ^a   Bettiol, S S ^b   Perera, R ^a   Roberts, N W ^a   Javaid, M K ^c   Farmer, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b School of Medicine   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adherence; Anti resorptive therapy; Meta analysis; Osteoporosis; Persistence

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; RALOXIFENE; RISEDRONIC ACID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COOPERATION; DRUG USE; FEMALE; FRACTURE; HIGH RISK POPULATION; HUMAN; META ANALYSIS; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT REFUSAL;

BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PATIENT COMPLIANCE;

EID: 78649351378     PISSN: 02632136     EISSN: 14602229     Source Type: Journal    
DOI: 10.1093/fampra/cmq060     Document Type: Review

References (25)

1. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-7.
2. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997; 103: 12S-7. discussion 7S-9S.
3. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ III. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993; 137: 1001-5.
4. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 160. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmeno-pausal women. London, England: National Institute for Health and Clinical Excellence, 2008.
5. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 161. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for secondary prevention of osteoporotic fragility fractures in postmeno-pausal women. London, England: National Institute for Health and Clinical Excellence, 2008.
6. Cranney A, Guyatt G, Griffith L et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-8.
7. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-7.
8. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 18: 1023-31.
9. Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 2010; 15: S529.
10. Rossini M, Bianchi G, Di Munno O et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006; 17: 914-21.
11. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006; 119 (4 suppl 1): S12-7.
12. Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims data-bases. Mayo Clin Proc 2006; 81: 1013-22.
13. Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR. Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ 2005; 330: 1179.
14. Wong SS, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc 2006; 94: 41-7.
15. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring in-consistency in meta-analyses. BMJ 2003; 327: 557-60.
17. Clowes JA, Peel NF, Eastell R. The impact of monitoring on ad-herence and persistence with antiresorptive treatment for post-menopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 1117-23.
18. Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006; 60: 896-905.
19. Delmas PD, Vrijens B, Eastell R et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007; 92: 1296-304.
20. Schousboe JT, Debold CR, Kuno LS et al. Education and phone follow-up in post menopausal women at risk of osteoporosis. Effects of Calcium intake, Exercise Frequency, and Medication Use. Dis Manage Health Outcomes 2005; 13: 395-404.
21. Guilera M, Fuentes M, Grifols M, Ferrer J, Badia X. Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos Int 2006; 17: 664-71.
22. Oakley S, Walley T. A pilot study assessing the effectiveness of a decision aid on patient adherence with oral bisphosphonate medication. Pharm J 2006; 6: 536-8.
23. Lydick E, Cook K, Turpin J et al. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care 1998; 4: 37-48.
24. Gertz BJ, Holland SD, Kline WF et al. Studies of the oral bio-availability of alendronate. Clin Pharmacol Ther 1995; 58: 288-98.
25. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540-50.